Cost-effectiveness of intermediate or long-acting insulin versus Exenatide in type 2 diabetes mellitus patients not optimally controlled on dual oral diabetes medications
Objective: To better understand exenatides role inthe treatment of type 2 diabetes, this analysisassessed its cost-effectiveness in comparison to anintermediate (NPH) and long-acting insulin(glargine). Exenatide is a recently approvedmedication for the treatment of type 2 diabetes foruse in additio...
Gardado en:
| Publicado en: | Pharmacy Practice |
|---|---|
| Principais autores: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Centro de investigaciones y Publicaciones Farmacéuticas
2006
|
| Assuntos: | |
| Acceso en liña: | https://www.redalyc.org/articulo.oa?id=69040305 |
| Tags: |
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|